Velorum Therapeutics, founded with the mission to revolutionize cancer treatment, focuses on developing innovative drugs that starve tumors by hijacking cancer metabolism. Their core vision is to offer groundbreaking therapies that significantly improve patient outcomes, starting with the most lethal forms of cancer. Velorum's primary product line includes a new class of cancer drugs designed to inhibit tumor growth, with initial human clinical trials set to commence soon, targeting lung cancer.

Notable figures affiliated with Velorum Therapeutics include leading oncologists and researchers who have contributed to the development of their proprietary treatments. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in their approach and potential impact. Key achievements include successful preclinical trials in mice, demonstrating the efficacy of their drugs. Velorum's work promises to make a substantial impact on cancer treatment, offering hope for more effective therapies against aggressive cancers.